93426-60-9
Chemical Structure
P-536
- CAS No.: 93426-60-9
- Formula:C44H39N3O19S
- Molecular Weight:945.86
IUPAC Name: (2R,3R,4S,5R,6R)-2-((benzoyloxy)methyl)-6-((((((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)sulfonyl)carbamoyl)oxy)tetrahydro-2H-pyran-3,4,5-triyl tribenzoate
InChIKey: SUAOMMKFCCTVDC-NSIBRLCRSA-N
SMILES: O(C(=O)C1=CC=CC=C1)[C@@H]2[C@@H](OC(=O)C3=CC=CC=C3)[C@@H](OC(NS(OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)N5C(=O)NC(=O)C=C5)(=O)=O)=O)O[C@H](COC(=O)C6=CC=CC=C6)[C@H]2OC(=O)C7=CC=CC=C7
Biological Activity: P-536 is a ACE inhibitor that also inhibits herpes simplex virus HSV-1 thymidine kinase and Trypanosoma cruzi RNA polymerase. By inhibiting the renin-angiotensin system, downregulating the expression of AT1R and NOX4, and reducing oxidative stress (decreasing plasma hydrogen peroxide (H2O2) and 8-isoprostaglandin levels), P-536 effectively reduces systolic blood pressure and improves vascular reactivity. P-536 also inhibits the replication of DNA/RNA viruses such as HSV-1 by blocking nucleotide metabolism and nucleic acid synthesis, competitively inhibits RNA synthesis in Trypanosoma cruzi, and inhibits amastigote replication, thereby impeding its growth. P-536 is suitable for research on hypertension, insulin resistance, and Chagas disease[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
P-536 | P-536 is a ACE inhibitor that also inhibits herpes simplex virus HSV-1 thymidine kinase and Trypanosoma cruzi RNA polymerase. By inhibiting the renin-angiotensin system, downregulating the expression of AT1R and NOX4, and reducing oxidative stress (decreasing plasma hydrogen peroxide (H2O2) and 8-isoprostaglandin levels), P-536 effectively reduces systolic blood pressure and improves vascular reactivity. P-536 also inhibits the replication of DNA/RNA viruses such as HSV-1 by blocking nucleotide metabolism and nucleic acid synthesis, competitively inhibits RNA synthesis in Trypanosoma cruzi, and inhibits amastigote replication, thereby impeding its growth. P-536 is suitable for research on hypertension, insulin resistance, and Chagas disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Nyby M D, et al. P-536: Inhibition of the renin-angiotensin system reduces vascular oxidative stress and vascular dysfunction in insulin-resistant rats[J]. American Journal of Hypertension, 2005, 18(S4): 202A-202A.
- [2]. Stanley A G, et al. P-536: Hypertensive subjects with increased leukocyte oxidative damage have shorter telomere DNA[J]. American Journal of Hypertension, 2002, 15(S3): 227A-227A.
- [3]. Alarcón B, et al. Mode of action of a new type of UDP-glucose analog against herpesvirus replication. Antimicrob Agents Chemother. 1988;32(8):1257-1261. [Content Brief]
- [4]. Alcina A, et al. Activity of P536, a UDP-glucose analog, against Trypanosoma cruzi. Antimicrob Agents Chemother. 1988;32(9):1412-1415. [Content Brief]
Keywords
